Anti-cd16 binding molecules
AssigneeAffimed Therapeutics, AG
InventorsKarin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
Life of this patent
Estimating the term…
Loading patent…
AssigneeAffimed Therapeutics, AG
InventorsKarin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
Estimating the term…
The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. FcγRIIIA), and in particular binding molecules that specifically bind the A form FcγRIII but do not bind to the B form of FcγRIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.
A binding molecule having specificity for at least one antigen, wherein the at least one antigen is FcgRIIIA and wherein the binding molecule does not specifically bind to FcgRIIIB.
Dependencies are inferred from the claim text.